Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 111 to 120 of 123 total matches.
Addendum: Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Mar 23, 2020 (Issue 1594)
Addendum: Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive ...
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18),
the drospirenone-only oral contraceptive, we mentioned that
drospirenone has antiandrogenic activity that could improve
acne and antimineralocorticoid activity that could cause
hyperkalemia. We should have added that concurrent use of
drospirenone with other drugs that increase potassium levels,
such as the anti-androgen aldosterone receptor antagonist
spironolactone (Aldactone, and generics), which is often
used off-label for treatment of acne, can increase the risk of
hyperkalemia.
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive ...
The FDA has approved a progestin-only oral
contraceptive ("minipill") containing drospirenone
(Slynd – Exeltis). All other progestin-only oral
contraceptives available in the US contain
norethindrone (Camila, and others). Progestin-only oral
contraceptives are similar in efficacy to combination
oral contraceptives. They are used predominantly by
breastfeeding women and by those in whom estrogen
is poorly tolerated or contraindicated. Combination
oral contraceptives containing drospirenone and
ethinyl estradiol have been available for years.
Brolucizumab (Beovu) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
potential who are receiving brolucizumab are
advised to use an effective method of contraception
during ...
Brolucizumab-dbll (Beovu — Novartis), a vascular
endothelial growth factor (VEGF) inhibitor, has been
approved by the FDA as an intravitreal injection for
treatment of neovascular (wet) age-related macular
degeneration (AMD). It is the fourth VEGF inhibitor to
be approved in the US for this indication; bevacizumab
(Avastin, and others), a VEGF inhibitor FDA-approved
for treatment of breast cancer and other malignancies,
has been used off-label for this indication for years.
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Jan 13, 2020 (Issue 1589)
patients, particularly in those who were also
taking hormonal contraceptives. Lens opacities ...
The FDA has approved Trikafta (Vertex), a fixed-dose
combination of the cystic fibrosis transmembrane
conductance regulator (CFTR) modulators elexacaftor,
tezacaftor, and ivacaftor, for oral treatment of cystic
fibrosis (CF) in patients ≥12 years old who have at
least one Phe508del mutation in the CFTR gene. About
90% of patients with CF have at least one copy of the
Phe508del (also called F508del) mutation. This is the
first approval for elexacaftor. Ivacaftor is available
alone (Kalydeco) and in 2-drug combinations with
tezacaftor (Symdeco) and lumacaftor...
Drugs for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019 (Issue 1588)
decrease the INR in patients who are taking warfarin.
Use of leflunomide with oral contraceptives can ...
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for treatment
of psoriatic arthritis have recently been published.
Annovera - A New Contraceptive Vaginal Ring
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
Annovera - A New Contraceptive Vaginal Ring ...
Annovera (TherapeuticsMD), a contraceptive vaginal
ring that releases segesterone acetate, a synthetic
progestin, and ethinyl estradiol, was approved by the
FDA in 2018 and is now available. It is the first product
to contain segesterone and the second vaginal ring
to become available in the US; NuvaRing, which
delivers etonogestrel and ethinyl estradiol, was the
first. Unlike NuvaRing, which requires use of a new
ring each month, the Annovera ring can be used for
an entire year, but it must be removed for one week
each month.
Darolutamide (Nubeqa) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
age should be advised to
use effective contraception during treatment with
darolutamide and for one ...
The FDA has approved darolutamide (Nubeqa –
Bayer), an androgen receptor inhibitor, for oral
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC). Darolutamide is the third
androgen receptor inhibitor to be approved for this
indication; apalutamide (Erleada) and enzalutamide
(Xtandi), which are also approved for use in patients
with metastatic castration-resistant prostate cancer
(mCRPC), were approved earlier.
Upadacitinib (Rinvoq) - A New JAK Inhibitor for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
. Women who could become pregnant
should use effective contraception while taking
upadacitinib and for 4 ...
The FDA has approved upadacitinib (Rinvoq –
Abbvie), an oral Janus kinase (JAK) inhibitor, for
treatment of adults with moderately to severely
active rheumatoid arthritis (RA) who have had
an inadequate response to or cannot tolerate
methotrexate (Trexall, and others). Upadacitinib is
the third JAK inhibitor to be approved in the US for
treatment of RA; tofacitinib (Xeljanz, Xeljanz XR)
and baricitinib (Olumiant) were approved earlier.
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
who are pregnant. Women of
childbearing potential should use effective contraception during ...
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
of
childbearing age should use effective contraception
during treatment.
There are no data on the presence ...
The FDA has approved bremelanotide (Vyleesi – Amag),
a melanocortin receptor agonist, for subcutaneous
treatment of premenopausal women with acquired,
generalized hypoactive sexual desire disorder (HSDD).
Bremelanotide is not approved for use in men or
postmenopausal women. It is the second drug to
be approved in the US for this indication; flibanserin
(Addyi), which was approved in 2015, was the first.